期刊文献+

甲磺酸沙芬酰胺有关物质的合成

Synthesis of the Related Substance of Safinamide Mesylate
原文传递
导出
摘要 为控制甲磺酸沙芬酰胺产品的质量,本研究合成了有关物质A,即(S)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄胺基]-丙酰胺。用对溴苯甲醚(7)与间氟苯甲酰氯(8)在Lewis酸催化下制得(5-溴-2-羟基苯基)(3-氟苄基)甲酮(9)。9经还原后,与间氟溴苄(11)经取代反应生成4-溴-2-(3-氟苄基)-1-(3-氟苄氧基)苯(12),随后经溴锂交换/甲酰化反应,生成3-(3-氟苄基)-4-(3-氟苄氧基)苯甲醛(13)。13与L-丙氨酰胺盐酸盐发生还原胺化得到有关物质A,总收率9.82%(以7计),结构经^(1)H NMR、^(13)C NMR和MS确证,可作为甲磺酸沙芬酰胺质量研究的对照物。 In order to control the quality of safinamide mesylate,the related substance A,named(S)-2-[[3-(3-fluorobenzyl)-4-[(3-fluorobenzyl)oxy]benzyl]amino]propanamide,was synthesized in this study.(5-Bromo-2-hydroxyphenyl)(3-fluorophenyl)methanone(9)was synthesized by the reaction of 4-bromoanisole(7)with 3-fluorobenzoyl chloride(8)catalyzed by Lewis acid.Compound 9 reduced in the presence of Et3SiH/BF_(3)·Et_(2)O,then reacted with 3-fluorobenzyl bromide(11)to give 4-bromo-2-(3-fluorobenzyl)-1-(3-fluorobenzyloxy)benzene(12),followed by lithium bromide exchange/formylation to give 3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)benzaldehyde(13).Related substance A was synthesized by reductive amination of 13 with L-alanamide hydrochloride,in an overall yield of 9.82%(based on 7).The structure of the product was confirmed by 1H NMR,13C NMR and MS,which could be used as the reference for quality control of safinamide mesylate.
作者 王进家 刘飞 高剑 柴雨柱 徐丹 朱春霞 WANG Jinjia;LIU Fei;GAO Jian;CHAI Yuzhu;XU Dan;ZHU Chunxia(Nanjing Chia Tai-Tianqing Pharmaceutical Co.,Ltd.,Nanjing 210046)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2021年第9期1187-1190,共4页 Chinese Journal of Pharmaceuticals
关键词 甲磺酸沙芬酰胺 有关物质 合成 safinamide mesylate related substance synthesis
  • 相关文献

参考文献3

二级参考文献70

  • 1桑艳双,魏敏吉.辅酶Q_(10)的生化作用机理和药物临床应用进展[J].中国医药导刊,2005,7(5):371-373. 被引量:21
  • 2杨宝峰.药理学[M].北京:人民卫生出版社,2006:247-248.
  • 3Braak H,Del Tredici K,Rub U,et al.Staging of brain pathology related to sporadic Parkinson's disease[J].Neurobiol,2003,24 (2):197-211.
  • 4Beyer K,Ariza A.Protein aggregation mechanisms in synucleinopathies:commonalities and differences[J].J Neuropathol Exp Neurol,2007,66(11):965-974.
  • 5Blindauer K.Delayed response to levodopa and response failures account for a large percentage of daily off time in advanced Parkinson's disease patients with motor fluctuations[J].Neurology,2003,60(1):81-82.
  • 6Tatton W,Chalmers-Redman R,Tatton N.Neuroprotection by deprenyl and other propargylamines:giyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B[J].J Neural Transm,2003,110(8):509-515.
  • 7Parkinson Study Group.A controlled trial of rasagiline in early Parkinson's disease:the TEMPO Study[J].Arch Neurol,2002,59(12):1937-1943.
  • 8Rascol O,Brooks DJ,Melamed E,et al.Rasagiline as an adjunt to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO,Lasting effect in Adjunct therapy with Rasagiline Given Once daily,study):a randomized double-blind,parallel-group trial[J].Lancet,2005,365 (9643):947-954.
  • 9Olanow CW,Hauser RA,Jankovic J,et al.A randomized,double-blind,placebo-controlled,delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's Disease (The ADAGIO Study):rationale,design and baseline characteristics[J].Mov Disord,2008,23 (15):2194-2201.
  • 10Stocchi F,Arnold G,Onofrj M,et al.Improvement of motor function in early Parkinson disease by safinamide[J].Neurology,2004,63 (4):746-748.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部